Europäische Union - Deutsch - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastische mittel - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

beigene switzerland gmbh - tislelizumabum - 100 mg / 10 ml konzentrat zur herstellung einer infusionslösung - tislelizumabum 100 mg, natrii citras dihydricus, acidum citricum monohydricum, histidini hydrochloridum monohydricum, histidinum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 16 mg. - onkologikum - biotechnologika